PPARδ inhibition blocks the induction and function of tumor-induced IL-10+ regulatory B cells and enhances cancer immunotherapy

[1]  Stanley J Tamaki,et al.  Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes , 2023, Cell.

[2]  B. Nelson,et al.  Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities , 2022, Nature Reviews Cancer.

[3]  Sean C. Bendall,et al.  Human IL-10-producing B cells have diverse states that are induced from multiple B cell subsets , 2022, Cell reports.

[4]  Y. Pylayeva-Gupta,et al.  Regulatory B cells in cancer , 2020, Immunological reviews.

[5]  E. Lipson,et al.  Neuropilin-1 is a T cell memory checkpoint limiting long-term anti-tumor immunity , 2020, Nature Immunology.

[6]  E. Song,et al.  Complement Signals Determine Opposite Effects of B Cells in Chemotherapy-Induced Immunity , 2020, Cell.

[7]  O. Britanova,et al.  B cells, plasma cells and antibody repertoires in the tumour microenvironment , 2020, Nature Reviews Immunology.

[8]  R. Vonderheide.  CD40 Agonist Antibodies in Cancer Immunotherapy. , 2020, Annual review of medicine.

[9]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[10]  J. Wargo,et al.  B cells are associated with survival and immunotherapy response in sarcoma , 2020, Nature.

[11]  D. Schadendorf,et al.  Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.

[12]  E. Meffre,et al.  B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors , 2019, Journal of Immunotherapy for Cancer.

[13]  Lening Zhang,et al.  Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma , 2019, Journal of bone oncology.

[14]  Howard Y. Chang,et al.  Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, bioRxiv.

[15]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[16]  J. Ravetch,et al.  Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity , 2018, Proceedings of the National Academy of Sciences.

[17]  Tristan T. Hays,et al.  The Nuclear Receptor PPAR&ggr; Controls Progressive Macrophage Polarization as a Ligand‐Insensitive Epigenomic Ratchet of Transcriptional Memory , 2018, Immunity.

[18]  D. Spaner,et al.  Peroxisome Proliferator-Activated Receptor–δ Supports the Metabolic Requirements of Cell Growth in TCRβ-Selected Thymocytes and Peripheral CD4+ T Cells , 2018, The Journal of Immunology.

[19]  C. Swanton,et al.  The function and dysfunction of memory CD8+ T cells in tumor immunity , 2018, Immunological reviews.

[20]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[21]  Johannes Griss,et al.  Tumor-associated B-cells induce tumor heterogeneity and therapy resistance , 2017, Nature Communications.

[22]  R. Martuza,et al.  Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.

[23]  Christopher J. Kane,et al.  Immunosuppressive plasma cells impede T cell-dependent immunogenic chemotherapy , 2015, Nature.

[24]  K. Takeda,et al.  Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. , 2014, Immunity.

[25]  C. Mauri,et al.  Immune regulatory function of B cells. , 2012, Annual review of immunology.

[26]  Chih-Hao Lee,et al.  Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. , 2008, Cell metabolism.

[27]  Vidya Subramanian,et al.  Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. , 2008, Cell metabolism.

[28]  Frank Brombacher,et al.  Macrophage-specific PPARγ controls alternative activation and improves insulin resistance , 2007, Nature.

[29]  W. Stadler,et al.  Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.